A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-120
SponsorUniversitaire Ziekenhuizen KU Leuven
About this trial
The main goal of this prospective non-interventional exploratory monocentric study is to characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from cancer patients experiencing cancer therapy-induced pneumonitis on a single-cell scale. These mechanistic insights can directly lead to putative diagnostic biomarkers and therapeutic targets.
A second highly clinically relevant hypothesis is that single-cell profiling of blood samples will reveal circulating biomarkers of ICB toxicity, making non-invasive diagnosis feasible.
Eligibility criteria
Qualifiers
Adult M/F/X (>= 18 years)
Patients receiving or having received treatment per guidelines
Patients undergoing bronchoscopy with BAL, for possible cancer treatment-induced pneumonitis
Not included in other clinical trials
Disqualifiers
None
Trial design
Treatments tested in this trial
- Immune checkpoint blockade
- Targeted therapy
- Radiotherapy
Treatment groups
60 Participants
are divided into 3 treatment groupsSponsors and collaborators
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
KU Leuven
Collaborator
Source ClinicalTrials.gov